U.S. market Closed. Opens in 2 days 4 hours 11 minutes

KRYS | Krystal Biotech, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 184.12 - 189.19
52 Week Range 109.57 - 219.34
Beta 0.77
Implied Volatility 46.99%
IV Rank 31.69%
Day's Volume 288,471
Average Volume 268,300
Shares Outstanding 28,760,500
Market Cap 5,402,947,530
Sector Healthcare
Industry Biotechnology
IPO Date 2017-09-20
Valuation
Profitability
Growth
Health
P/E Ratio 62.83
Forward P/E Ratio N/A
EPS 2.99
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 229
Country USA
Website KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
*Chart delayed
Analyzing fundamentals for KRYS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is very bad and Health is very strong. For more detailed analysis please see KRYS Fundamentals page.

Watching at KRYS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on KRYS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙